These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 14968938)

  • 21. Simian immunodeficiency virus is susceptible to inhibition by carbohydrate-binding agents in a manner similar to that of HIV: implications for further preclinical drug development.
    François KO; Auwerx J; Schols D; Balzarini J
    Mol Pharmacol; 2008 Aug; 74(2):330-7. PubMed ID: 18474667
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of siamycin I, a human immunodeficiency virus fusion inhibitor.
    Lin PF; Samanta H; Bechtold CM; Deminie CA; Patick AK; Alam M; Riccardi K; Rose RE; White RJ; Colonno RJ
    Antimicrob Agents Chemother; 1996 Jan; 40(1):133-8. PubMed ID: 8787894
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential effects of phorbol-13-monoesters on human immunodeficiency virus reactivation.
    Márquez N; Calzado MA; Sánchez-Duffhues G; Pérez M; Minassi A; Pagani A; Appendino G; Diaz L; Muñoz-Fernández MA; Muñoz E
    Biochem Pharmacol; 2008 Mar; 75(6):1370-80. PubMed ID: 18241838
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protein kinases C as potential host targets for the inhibition of chikungunya virus replication.
    Abdelnabi R; Amrun SN; Ng LF; Leyssen P; Neyts J; Delang L
    Antiviral Res; 2017 Mar; 139():79-87. PubMed ID: 28039020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chimeric HIV-1 containing SIV matrix exhibit enhanced assembly in murine cells and replicate in a cell-type-dependent manner in human T cells.
    Chen P; Hübner W; Riviere K; Liu YX; Chen BK
    Virology; 2006 May; 349(1):1-12. PubMed ID: 16563454
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).
    Geleziunas R; Gallagher K; Zhang H; Bacheler L; Garber S; Wu JT; Shi G; Otto MJ; Schinazi RF; Erickson-Viitanen S
    Antivir Chem Chemother; 2003 Jan; 14(1):49-59. PubMed ID: 12790516
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resistance of the human immunodeficiency virus to the inhibitory action of negatively charged albumins on virus binding to CD4.
    Cabrera C; Witvrouw M; Gutiérrez A; Clotet B; Kuipers ME; Swart PJ; Meijer DK; Desmyter J; De Clercq E; Esté JA
    AIDS Res Hum Retroviruses; 1999 Nov; 15(17):1535-43. PubMed ID: 10580404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanisms of HIV receptor and co-receptor down-regulation by prostratin: role of conventional and novel PKC isoforms.
    Hezareh M; Moukil MA; Szanto I; Pondarzewski M; Mouche S; Cherix N; Brown SJ; Carpentier JL; Foti M
    Antivir Chem Chemother; 2004 Jul; 15(4):207-22. PubMed ID: 15457682
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Low-Cost Compound Lignosulfonic Acid (LA) Exhibits Broad-Spectrum Anti-HIV and Anti-HSV Activity and Has Potential for Microbicidal Applications.
    Gordts SC; Férir G; D'huys T; Petrova MI; Lebeer S; Snoeck R; Andrei G; Schols D
    PLoS One; 2015; 10(7):e0131219. PubMed ID: 26132818
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A nonpromoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1.
    Gustafson KR; Cardellina JH; McMahon JB; Gulakowski RJ; Ishitoya J; Szallasi Z; Lewin NE; Blumberg PM; Weislow OS; Beutler JA
    J Med Chem; 1992 May; 35(11):1978-86. PubMed ID: 1597853
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
    Westby M; Smith-Burchnell C; Mori J; Lewis M; Mosley M; Stockdale M; Dorr P; Ciaramella G; Perros M
    J Virol; 2007 Mar; 81(5):2359-71. PubMed ID: 17182681
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of bovine immunodeficiency virus by anti-HIV-1 compounds in a cell culture-based assay.
    Tobin GJ; Ennis WH; Clanton DJ; Gonda MA
    Antiviral Res; 1996 Dec; 33(1):21-31. PubMed ID: 8955850
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates.
    De Meyer S; Azijn H; Surleraux D; Jochmans D; Tahri A; Pauwels R; Wigerinck P; de Béthune MP
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2314-21. PubMed ID: 15917527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Agents for treating human immunodeficiency virus infection.
    Acosta EP; Fletcher CV
    Am J Hosp Pharm; 1994 Sep; 51(18):2251-67; quiz 2286-7. PubMed ID: 7801986
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selection of human immunodeficiency virus type 1 resistance against the pyranodipyrimidine V-165 points to a multimodal mechanism of action.
    Hombrouck A; Hantson A; van Remoortel B; Michiels M; Vercammen J; Rhodes D; Tetz V; Engelborghs Y; Christ F; Debyser Z; Witvrouw M
    J Antimicrob Chemother; 2007 Jun; 59(6):1084-95. PubMed ID: 17470918
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tenofovir treatment augments anti-viral immunity against drug-resistant SIV challenge in chronically infected rhesus macaques.
    Metzner KJ; Binley JM; Gettie A; Marx P; Nixon DF; Connor RI
    Retrovirology; 2006 Dec; 3():97. PubMed ID: 17184540
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV.
    Hazen R; Harvey R; Ferris R; Craig C; Yates P; Griffin P; Miller J; Kaldor I; Ray J; Samano V; Furfine E; Spaltenstein A; Hale M; Tung R; St Clair M; Hanlon M; Boone L
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3147-54. PubMed ID: 17620375
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Actinohivin, a novel anti-human immunodeficiency virus protein from an actinomycete, inhibits viral entry to cells by binding high-mannose type sugar chains of gp120.
    Chiba H; Inokoshi J; Nakashima H; Omura S; Tanaka H
    Biochem Biophys Res Commun; 2004 Mar; 316(1):203-10. PubMed ID: 15003531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV.
    Gustchina E; Hummer G; Bewley CA; Clore GM
    J Med Chem; 2005 Apr; 48(8):3036-44. PubMed ID: 15828842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interferon inhibits the replication of HIV-1, SIV, and SHIV chimeric viruses by distinct mechanisms.
    Korth MJ; Taylor MD; Katze MG
    Virology; 1998 Aug; 247(2):265-73. PubMed ID: 9705919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.